Bio-Techne Co. (NASDAQ:TECH – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $80.60.
TECH has been the topic of a number of recent research reports. Robert W. Baird upped their target price on shares of Bio-Techne from $81.00 to $82.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Benchmark reissued a “buy” rating and set a $95.00 price objective on shares of Bio-Techne in a research note on Tuesday, August 13th. Finally, Royal Bank of Canada lowered their target price on shares of Bio-Techne from $72.00 to $70.00 and set a “sector perform” rating for the company in a research note on Thursday, August 8th.
View Our Latest Report on Bio-Techne
Institutional Investors Weigh In On Bio-Techne
Bio-Techne Trading Down 2.6 %
Shares of TECH opened at $78.30 on Monday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.87 and a quick ratio of 2.75. Bio-Techne has a 1-year low of $51.79 and a 1-year high of $85.57. The stock has a market cap of $12.42 billion, a price-to-earnings ratio of 62.14, a price-to-earnings-growth ratio of 5.06 and a beta of 1.27. The firm has a 50 day simple moving average of $75.25 and a 200-day simple moving average of $73.99.
Bio-Techne (NASDAQ:TECH – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.49 earnings per share for the quarter, hitting the consensus estimate of $0.49. Bio-Techne had a return on equity of 12.88% and a net margin of 14.50%. The company had revenue of $306.10 million during the quarter, compared to the consensus estimate of $306.49 million. During the same quarter last year, the business posted $0.56 earnings per share. Bio-Techne’s revenue was up 1.6% compared to the same quarter last year. Equities analysts forecast that Bio-Techne will post 1.71 EPS for the current fiscal year.
Bio-Techne Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, August 30th. Stockholders of record on Monday, August 19th were paid a $0.08 dividend. This represents a $0.32 annualized dividend and a dividend yield of 0.41%. The ex-dividend date of this dividend was Monday, August 19th. Bio-Techne’s dividend payout ratio is currently 25.40%.
Bio-Techne Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
Further Reading
- Five stocks we like better than Bio-Techne
- Energy and Oil Stocks Explained
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What Are Dividends? Buy the Best Dividend Stocks
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- When to Sell a Stock for Profit or Loss
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.